Caribou Biosciences (CRBU) Competitors $0.73 -0.06 (-7.01%) As of 10:08 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRBU vs. RAPP, SLDB, HRTX, ALLO, ARCT, ATXS, GLUE, CYRX, AURA, and ESPRShould you be buying Caribou Biosciences stock or one of its competitors? The main competitors of Caribou Biosciences include Rapport Therapeutics (RAPP), Solid Biosciences (SLDB), Heron Therapeutics (HRTX), Allogene Therapeutics (ALLO), Arcturus Therapeutics (ARCT), Astria Therapeutics (ATXS), Monte Rosa Therapeutics (GLUE), Cryoport (CYRX), Aura Biosciences (AURA), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical products" industry. Caribou Biosciences vs. Rapport Therapeutics Solid Biosciences Heron Therapeutics Allogene Therapeutics Arcturus Therapeutics Astria Therapeutics Monte Rosa Therapeutics Cryoport Aura Biosciences Esperion Therapeutics Caribou Biosciences (NASDAQ:CRBU) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, community ranking, risk, institutional ownership and media sentiment. Does the media refer more to CRBU or RAPP? In the previous week, Rapport Therapeutics had 3 more articles in the media than Caribou Biosciences. MarketBeat recorded 4 mentions for Rapport Therapeutics and 1 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.48 beat Rapport Therapeutics' score of 0.19 indicating that Caribou Biosciences is being referred to more favorably in the media. Company Overall Sentiment Caribou Biosciences Neutral Rapport Therapeutics Neutral Does the MarketBeat Community prefer CRBU or RAPP? Caribou Biosciences received 24 more outperform votes than Rapport Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Rapport Therapeutics an outperform vote while only 61.90% of users gave Caribou Biosciences an outperform vote. CompanyUnderperformOutperformCaribou BiosciencesOutperform Votes2661.90% Underperform Votes1638.10% Rapport TherapeuticsOutperform Votes2100.00% Underperform VotesNo Votes Do analysts recommend CRBU or RAPP? Caribou Biosciences presently has a consensus target price of $10.33, suggesting a potential upside of 1,216.35%. Rapport Therapeutics has a consensus target price of $35.00, suggesting a potential upside of 310.80%. Given Caribou Biosciences' higher probable upside, analysts plainly believe Caribou Biosciences is more favorable than Rapport Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Caribou Biosciences 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Rapport Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, CRBU or RAPP? Rapport Therapeutics has lower revenue, but higher earnings than Caribou Biosciences. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCaribou Biosciences$9.99M7.31-$102.07M-$1.65-0.48Rapport TherapeuticsN/AN/A-$34.79M-$13.84-0.62 Is CRBU or RAPP more profitable? Rapport Therapeutics has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,290.81%. Rapport Therapeutics' return on equity of 0.00% beat Caribou Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Caribou Biosciences-1,290.81% -45.46% -38.07% Rapport Therapeutics N/A N/A N/A Do institutionals & insiders hold more shares of CRBU or RAPP? 77.5% of Caribou Biosciences shares are held by institutional investors. 9.5% of Caribou Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryCaribou Biosciences beats Rapport Therapeutics on 9 of the 15 factors compared between the two stocks. Remove Ads Get Caribou Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRBU vs. The Competition Export to ExcelMetricCaribou BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$73.01M$2.98B$5.53B$7.50BDividend YieldN/A1.53%4.87%4.05%P/E Ratio-0.4830.4323.2118.08Price / Sales7.31383.25364.3786.83Price / CashN/A168.6838.1634.64Price / Book0.193.646.503.99Net Income-$102.07M-$72.06M$3.21B$247.18M7 Day Performance-16.41%-9.02%-4.91%-4.25%1 Month Performance-28.64%-16.50%-0.08%-6.87%1 Year Performance-82.71%-31.37%6.54%-3.73% Caribou Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRBUCaribou Biosciences2.9528 of 5 stars$0.73-7.0%$10.33+1,315.5%-83.2%$67.80M$9.99M-0.44100Short Interest ↓Gap DownRAPPRapport Therapeutics1.6086 of 5 stars$10.22+5.1%$35.00+242.5%N/A$372.99MN/A-0.74N/AShort Interest ↑Gap DownSLDBSolid Biosciences3.0414 of 5 stars$4.78+3.9%$15.67+227.8%-72.8%$370.42M$8.09M-1.57100Gap DownHRTXHeron Therapeutics3.2015 of 5 stars$2.43+2.1%$5.67+133.2%-16.7%$370.16M$144.29M-13.50300Positive NewsALLOAllogene Therapeutics2.3359 of 5 stars$1.68+3.7%$9.29+452.9%-66.3%$365.01M$22,000.00-1.08310Analyst RevisionGap DownARCTArcturus Therapeutics3.1668 of 5 stars$13.27+3.0%$59.20+346.1%-71.0%$359.88M$138.39M-5.98180Positive NewsGap DownATXSAstria Therapeutics1.4554 of 5 stars$6.37-0.6%$26.67+318.6%-57.4%$359.49MN/A-3.0530Gap DownGLUEMonte Rosa Therapeutics3.0054 of 5 stars$5.83+0.5%$15.50+165.9%-43.9%$358.18M$14.98M-3.1990Short Interest ↓CYRXCryoport2.5868 of 5 stars$7.10+24.8%$11.67+64.3%-70.3%$354.36M$228.39M-2.101,020Analyst ForecastGap DownHigh Trading VolumeAURAAura Biosciences2.0989 of 5 stars$7.00-6.7%$23.00+228.6%-21.8%$349.66MN/A-4.0550Gap DownHigh Trading VolumeESPREsperion Therapeutics3.695 of 5 stars$1.74+3.0%$6.75+287.9%-58.7%$344.26M$332.31M-2.72200 Remove Ads Related Companies and Tools Related Companies Rapport Therapeutics Competitors Solid Biosciences Competitors Heron Therapeutics Competitors Allogene Therapeutics Competitors Arcturus Therapeutics Competitors Astria Therapeutics Competitors Monte Rosa Therapeutics Competitors Cryoport Competitors Aura Biosciences Competitors Esperion Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRBU) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caribou Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caribou Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
